Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study

Autor: Jing Bo Liang, Jing Tang, Xiaobing Li, De Wu, Xu Yong Li, Li Peng
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
Male
Cancer Research
Lung Neoplasms
Pyridines
medicine.medical_treatment
chemistry.chemical_compound
Antiangiogenesis therapy
0302 clinical medicine
Carcinoma
Non-Small-Cell Lung
Antineoplastic Combined Chemotherapy Protocols
Apatinib
Molecular Targeted Therapy
Neoplasm Metastasis
General Medicine
Middle Aged
Rash
Magnetic Resonance Imaging
Pemetrexed
Treatment Outcome
Docetaxel
030220 oncology & carcinogenesis
Adenocarcinoma
Female
medicine.symptom
medicine.drug
medicine.medical_specialty
Non-small cell lung cancer (NSCLC)
Cytotoxic chemotherapy
Article
03 medical and health sciences
Internal medicine
medicine
Biomarkers
Tumor
Humans
Protein Kinase Inhibitors
Aged
Neoplasm Staging
Chemotherapy
Performance status
business.industry
medicine.disease
Survival Analysis
030104 developmental biology
chemistry
Neoplasm Grading
business
Tomography
X-Ray Computed
Progressive disease
Zdroj: Oncology Research
ISSN: 1555-3906
0965-0407
Popis: Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an antiangiogenic agent has been shown to be a feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical activity. With this in mind, we investigated the efficiency of apatinib in combination with pemetrexed or docetaxel in advanced NSCLC. We treated a total of 20 patients with metastatic NSCLC adenocarcinoma with apatinib in combination with either pemetrexed or docetaxel from January 2016 to March 2017. The performance status of these patients was 0 or 1. All of these patients had been previously treated with two or more lines of treatment and had experienced disease progression prior to study enrollment. The overall objective response rate (ORR) was 30%, with 6 patients who had partial response (PR), 10 patients who had stable disease (SD), and 4 patients who had progressive disease (PD). The main adverse events were skin rash, hypertension, palmar‐plantar erythrodysesthesia syndrome, diarrhea, and fatigue. Nearly 30% of patients required interruption of treatment as a result of toxicity. Our study demonstrated that apatinib combined with systemic cytotoxic chemotherapy has clinical efficacy in patients with disease-refractory metastatic NSCLC and provides evidence for further studies investigating apatinib-based combination regimens.
Databáze: OpenAIRE
Externí odkaz: